The earnings call reflected a positive outlook with significant financial growth, clinical progress in key trials, and strategic leadership enhancements. However, there are challenges related to the timing of clinical operations and dependency on regulatory changes, which could impact future trial designs and approvals.

Company Guidance

During the Altimmune Third Quarter 2025 Financial Results Conference Call, the company provided detailed guidance on several key metrics. The upcoming Q4 milestone includes the 48-week IMPACT data readout, which is anticipated to demonstrate continued efficacy of pemvidutide for MASH, building upon the 24-week data that showed rapid efficacy and compelling antifibrotic activity. The in-person end of Phase II meeting with the FDA in Q4, recently granted, is expected to solidify the Phase III program's design. Financially, Altimmune's balance sheet has strengthened with a 60% increase in total cash, reaching $211 million by September 30, 2025, supported by $127 million raised in the year and an amended debt agreement with Hercules. The RECLAIM Phase II trial for AUD completed enrollment ahead of schedule, highlighting significant interest in pemvidutide. Additionally, the company began enrolling the ALD Phase II trial in the third quarter. Recent executive team expansions aim to support the next phase of growth, including the appointments of new Chief Medical, Commercial, and Legal Officers.

Strong Financial Position

Total cash increased by 60% over the start of the year, reaching $211 million. Raised $127 million through the first 9 months of the year.

Pemvidutide Clinical Progress

Completed enrollment in the RECLAIM Phase II trial of pemvidutide in AUD, ahead of schedule. Initiated ALD Phase II trial enrollment.

Positive Clinical Data

24-week data from the IMPACT trial showed rapid and robust MASH resolution with statistical significance, compelling antifibrotic activity, and weight loss.

Upcoming Milestones

Expecting 48-week data from the IMPACT trial by year-end and an in-person end of Phase II meeting with the FDA.

Talent Expansion

Expansion of leadership team with new appointments: Chief Medical Officer, Chief Commercial Officer, and Chief Legal Officer.

Altimmune (ALT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 26, 2026	2025 (Q4)	-0.26 / -	-0.33	―	―	―
Nov 06, 2025	2025 (Q3)	-0.27 / -0.21	-0.32	34.38% (+0.11)	―
Aug 12, 2025	2025 (Q2)	-0.34 / -0.27	-0.35	22.86% (+0.08)	―
May 13, 2025	2025 (Q1)	-0.35 / -0.26	-0.34	23.53% (+0.08)	―
Feb 27, 2025	2024 (Q4)	-0.33 / -0.33	-0.54	38.89% (+0.21)	―
Nov 12, 2024	2024 (Q3)	-0.36 / -0.32	-0.39	17.95% (+0.07)	―
Aug 08, 2024	2024 (Q2)	-0.35 / -0.35	-0.32	-9.37% (-0.03)	―
May 09, 2024	2024 (Q1)	-0.37 / -0.34	-0.4	15.00% (+0.06)	―
Mar 27, 2024	2023 (Q4)	-0.46 / -0.54	-0.43	-25.58% (-0.11)	―
Nov 07, 2023	2023 (Q3)	-0.45 / -0.39	-0.48	18.75% (+0.09)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$3.75	$3.94	+5.07%
Aug 12, 2025	$3.38	$3.62	+7.10%
May 13, 2025	$6.01	$5.76	-4.16%
Feb 27, 2025	$5.94	$6.42	+8.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Altimmune Inc (ALT) report earnings?

Altimmune Inc (ALT) is schdueled to report earning on Mar 26, 2026, TBA (Confirmed).

What is Altimmune Inc (ALT) earnings time?

Altimmune Inc (ALT) earnings time is at Mar 26, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALT EPS forecast?

ALT EPS forecast for the fiscal quarter 2025 (Q4) is -0.26.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing